In a Monday press release, Sucampo Pharmaceuticals (NASDAQ:SCMP) and Abbott Laboratories (NYSE:ABT) have reported the availability in Japan of Amitiza (lubiprostone), which is a prescription medicine for the treatment of chronic constipation that is not caused by organic diseases. The drug was okayed by Japan’s Ministry of Health, Labor and Welfare in June.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Johnson & Johnson’s (NYSE:JNJ) unit that is developing a proposed experimental drug to treat a drug-resistant form of tuberculosis, saw the FDA call it “safe and well-tolerated’ on Monday. The medication is called bedaquiline, and the firm is requesting an accelerated approval.
The biopharmaceutical firm Amarin Corporation (NASDAQ:AMRN) reports through a press release that the United States Patent and Trademark Office has published a notification of Notice of Allowance for United States Patent Application Serial Number 13/610,247, to protect the Vascepa (icosapent ethyl) indication that was cleared in July by the FDA, based upon Amarin’s Marine clinical trial results. The company concentrates on the commercialization and development of therapeutics through which to improve cardiovascular health.
Investing Insights: Is Pfizer’s Stock a Buy with Lyrica?